Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Ki-1+ Anaplastic Large Cell Lymphoma
0.700 AlteredExpression disease BEFREE ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population. 29150811 2018
Ki-1+ Anaplastic Large Cell Lymphoma
0.700 Biomarker disease BEFREE Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations. 28356514 2018
Ki-1+ Anaplastic Large Cell Lymphoma
0.700 GeneticVariation disease BEFREE The anaplastic lymphoma kinase (ALK) gene was initially identified as a fusion partner of the nucleophosmin gene in anaplastic large-cell lymphoma with t(2;5)(p23;q35) translocation, and then described with different genetic abnormalities in a number of tumors. 28756644 2017
Ki-1+ Anaplastic Large Cell Lymphoma
0.700 Biomarker disease BEFREE NPM-ALK phosphorylates WASp Y102 and contributes to oncogenesis of anaplastic large cell lymphoma. 27694894 2017
Ki-1+ Anaplastic Large Cell Lymphoma
0.700 GeneticVariation disease BEFREE Anaplastic lymphoma kinase-positive (ALK+) anaplastic large-cell lymphoma (ALCL) is characterized by expression of oncogenic ALK fusion proteins due to the translocation t(2;5)(p23;q35) or variants. 28581487 2017
Ki-1+ Anaplastic Large Cell Lymphoma
0.700 Biomarker disease BEFREE Anaplastic lymphoma kinase (ALK) is correlated with oncogenesis in different types of cancers, such as anaplastic large cell lymphoma, lung cancer, neuroblastoma, and even breast cancer, by abnormal fusion of ALK or non-fusion ALK activation. 26529396 2016
Ki-1+ Anaplastic Large Cell Lymphoma
0.700 Biomarker disease BEFREE In reactive lymphoid tissues, only a few histiocytes were positive for napsin A. ALK-positive ALCLs most frequently expressed napsin A (34.4%, 11/32 cases) at a rate that was significantly higher compared with ALK-negative ALCL (8.6%, 3/35; P=0.015). 26400099 2016
Ki-1+ Anaplastic Large Cell Lymphoma
0.700 AlteredExpression disease BEFREE Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. 26463425 2016
Ki-1+ Anaplastic Large Cell Lymphoma
0.700 Biomarker disease BEFREE The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase was initially discovered as a component of the fusion protein nucleophosmin (NPM)-ALK in anaplastic large-cell lymphoma (ALCL). 25979929 2016
Ki-1+ Anaplastic Large Cell Lymphoma
0.700 AlteredExpression disease BEFREE Anaplastic large cell lymphoma (ALCL) is divided into two systemic diseases according to the expression of the anaplastic lymphoma kinase (ALK). 25688981 2016
Ki-1+ Anaplastic Large Cell Lymphoma
0.700 Biomarker disease BEFREE Altogether, our results suggest that co-treatment with crizotinib and chloroquine (two drugs already used in clinics) could be beneficial for ALK-positive ALCL patients. 26338968 2016
Ki-1+ Anaplastic Large Cell Lymphoma
0.700 Biomarker disease BEFREE Recent clinical, pathologic, and genetic data have begun to shed light on ALK-negative ALCLs, revealing significant heterogeneity within this more ill-defined entity. 26104084 2016
Ki-1+ Anaplastic Large Cell Lymphoma
0.700 Biomarker disease BEFREE This work defines reliable ALCL model systems of AP26113 resistance and provides a valuable tool in the management of all cases of relapse upon NPM-ALK-targeted therapy. 25421750 2016
Ki-1+ Anaplastic Large Cell Lymphoma
0.700 GeneticVariation disease BEFREE ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors. 25874976 2016
Ki-1+ Anaplastic Large Cell Lymphoma
0.700 Biomarker disease BEFREE Here we present a model of peripheral ALCL pathogenesis where the malignancy is initiated in early thymocytes, before T-cell receptor (TCR) β-rearrangement, which is bypassed in CD4/NPM-ALK transgenic mice following Notch1 expression. 26753883 2016
Ki-1+ Anaplastic Large Cell Lymphoma
0.700 Biomarker disease BEFREE However, overexpression of CCR8 has also been reported in systemic ALK-negative ALCLs. 25390351 2016
Ki-1+ Anaplastic Large Cell Lymphoma
0.700 AlteredExpression disease BEFREE AE: adverse event; ALCL: anaplastic large cell lymphoma; ALK: anaplastic lymphoma kinase; ASCT: autologous stem cell transplant; BEAM: BCNU/carmustine, etoposide, ara-C, and melphalan; BV: brentuximab vedotin; CHEOP: cyclophosphamide, daunorubicin, vincristine, prednisone, etoposide; CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone; CR:complete response; G3+: grade 3 or higher; MTD: maximum tolerated dose; ORR: overall response rate; OS: overall survival; PFS: progression-free survival. 26809026 2016
Ki-1+ Anaplastic Large Cell Lymphoma
0.700 GeneticVariation disease BEFREE For example, genetic alterations have been discovered, including signal transducer and activator of transcription (STAT)3 and STAT5b mutations in several PTCLs, disease-specific ras homolog family member A (RHOA) mutations in angioimmunoblastic T cell lymphoma (AITL), and recurrent translocations at the dual specificity phosphatase 22 (DUSP22) locus in anaplastic lymphoma receptor tyrosine kinase (ALK)-negative anaplastic large cell lymphomas (ALCLs). 26431836 2016
Ki-1+ Anaplastic Large Cell Lymphoma
0.700 Biomarker disease BEFREE As proof-of-principle, we apply hiBA-FISH to detect with high sensitivity and specificity rare chromosome breaks and translocations in the anaplastic large cell lymphoma breakpoint regions of NPM1 and ALK. 26313373 2016
Ki-1+ Anaplastic Large Cell Lymphoma
0.700 Biomarker disease BEFREE ALK-positive (2p23 rearranged) anaplastic large cell lymphoma with localization to the skin in a pediatric patient. 25404214 2016
Ki-1+ Anaplastic Large Cell Lymphoma
0.700 Biomarker disease BEFREE Anaplastic lymphoma kinase-positive (ALK+) anaplastic large-cell lymphoma (ALCL) is an aggressive T-cell non-Hodgkin lymphoma characterized by the t(2;5), resulting in the overexpression of nucleophosmin (NPM)-ALK, which is known to activate the phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, resulting in cell cycle and apoptosis deregulation. 25987255 2016
Ki-1+ Anaplastic Large Cell Lymphoma
0.700 Biomarker disease BEFREE Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements. 26379151 2016
Ki-1+ Anaplastic Large Cell Lymphoma
0.700 AlteredExpression disease BEFREE Given the fact that ALK+ ALCL exhibits high levels of apoptosis and is typically responsive to conventional chemotherapy, we examined whether GzB expression might play a role in sensitizing ALK+ ALCL tumour cells to apoptosis. 25168906 2016
Ki-1+ Anaplastic Large Cell Lymphoma
0.700 GeneticVariation disease BEFREE Rearrangements of the anaplastic lymphoma kinase (ALK) gene originally discovered nearly 20 years ago in the context of anaplastic large cell lymphoma were identified as oncogenic drivers in a subset of non-small cell lung cancers (NSCLCs) in 2007. 26076736 2016
Ki-1+ Anaplastic Large Cell Lymphoma
0.700 Biomarker disease BEFREE Hodgkin's lymphoma (HL) and ALK(+) anaplastic large-cell lymphoma (ALCL) have become highly curable due to the success of modern regimens of chemotherapy and radiotherapy. 24043362 2015